



## 2020 AMAG Pharmaceuticals Research Grant Application Form

You are invited to submit grant proposals focused on reducing premature birth and preeclampsia in order to improve the health of mothers, neonates and infants in the United States. An independent external review committee will evaluate the proposals and determine funding. The total funds available are \$250,000; the maximum a single recipient can receive is \$50,000 to allow for multiple grants to be provided.

**\*\*\*All applications must be submitted by June 30, 2020 \*\*\***

**Applications should include the following:**

**Title of proposal**

**Name of Principal Investigator**

**Contact information**

*Please submit additional information in the format as described.*

**1. Proposal abstract** (*limit to 300 words*)

**2. Proposal body** (*limit to 8 pages single space 11 points font, not including references*):

**2.1. Specific aims** (*not more than 1 page*)

*Briefly introduce the problem that this project will address and its significance, followed by a statement of the short and long term objectives. This should then be followed by the specific aims, along with a brief description of what will be investigated under these aims. Close by discussing the significance of your project and the unique contribution to the field (e.g., providing new knowledge, changing practice, pilot data, etc.) and how it fits with the goals of improving maternal and neonatal health. Include statement of specific aims as appropriate.*

**2.2. Background**

*The background should explain why the proposed project is important. The rationale for each aim should be grounded in relevant evidence; highlighting the nature of the problem to be addressed. Please describe other related work underway by you or others, and reference published and completed work. This*

*section should convince the reviewer of the need to perform this project. If the project is a subsequent phase of previous work, please summarize how the new work will enhance or extend previous accomplishments and outcomes.*

### 2.3. Methods

Include *(as appropriate for the proposal)*:

- a. Aims or questions to be addressed *(clear statement of hypotheses)*
- b. Proposed design and conceptual framework
- c. Detailed methodology including:
  - i. How data will be collected or obtained
  - ii. How cases and controls will be defined and identified
  - iii. How comparisons will be made
  - iv. Analytic plan
  - v. Approaches to help minimize bias
  - vi. Sampling methodology and power calculations
  - vii. Strengths and weaknesses of your methodology
- g. Measures of success
- h. Project limitations

### 2.4. Anticipated outcomes

### 2.5. Significance *(include impact on maternal and neonatal health, and personal advancement)*

### 2.6. Timeline

### 2.7. Environment *(half a page)*

Describe available support and infrastructure to complete the project

### 2.8. Investigators *(half a page)*

Describe why you and your co-investigators/consultants are uniquely qualified to perform this project

## 3. Budget and justification *(limit to 1 page)*

### **Not allowed:**

- a. Salary for PI



- b. Overhead or indirect costs
- c. Computer or equipment

**Examples of allowable items** (*with appropriate justification*):

- a. Animal and reagent charges
- b. Laboratory and imaging tests (at research costs)
- c. Charges for access to databases
- d. Software to accomplish project
- e. Consultant
- f. Travel and lodging that is required to complete project (have to show that activities cannot be performed remotely)

**4. Biosketches for all involved** (*NIH format preferred*)

**5. Letters of support:**

- a. Fellowship program director if fellow, division director or chair if faculty, supervisor or direct report for others
- b. Any consultant or investigator who will be performing part of the work. Please include agreement as far as the scope of work and compensation, if applicable.

*Thank you for your submission. AMAG Pharmaceuticals is pleased to support research endeavors in this field. Please submit applications or questions to:*

[annual.prematurity.preeclampsia.grants@amagpharma.com](mailto:annual.prematurity.preeclampsia.grants@amagpharma.com)

*You will receive an e-mail confirming receipt of your application. Recipients will be announced by September 30, 2020.*